Raasch, Beverley, and Woolley, Torres (2006) Management of primary superficial basal cell carcinoma. Australian Family Physician, 35 (6). pp. 455-458.

Preview

PDF (Published Version) - Published Version Download (209kB)

 

6

1093

Abstract

BACKGROUND: Superficial basal cell carcinoma (SBCC) is a skin cancer commonly treated by general practitioners. Little is known about how GPs choose from the available treatment options. METHOD: A cross sectional survey was conducted by self administered questionnaire. RESULTS: Of 257 GPs surveyed, 107 responded (adjusted response rate 59%). Sixty-three percent reported treating more than two SBCC per month, managing 90% themselves, mostly by surgery (57%), and imiquimod 5% cream (19%). Forty percent of SBCC patients were referred to a plastic surgeon, and 26% (IQR 0-50%) to a general surgeon. Contraindications to surgery included lesion site (14%), and size (12%). Sixty-two percent of GPs reported never using curettage and cautery, and 23% never cryotherapy. If the cost of imiquimod 5% cream were to be subsidised through the Pharmaceutical Benefits Scheme, GPs predicted its use for SBCC would increase from 34 to 58% (p>0.001). DISCUSSION: General practitioners manage most lesions themselves and refer appropriately. Areas of educational need were identified with respect to management of inadequately treated or recurrent lesions.

Actions (Repository Staff Only)

Item Control Page